Core Points - The case involving individuals suspected of extorting Henan Lingrui Pharmaceutical Co., Ltd. has drawn significant attention in the pharmaceutical industry, with potential implications for how companies handle "parallel trading" behaviors [1][2] - The trial has been postponed multiple times, with the prosecution presenting evidence including testimonies and recordings to argue whether the actions constituted extortion [1][3] Group 1: Case Details - The defendants allegedly used false identities to establish relationships with pharmaceutical sales representatives and engaged in parallel trading, leading to extortion attempts against the companies involved [4][5] - Evidence presented in court included recordings of conversations where the defendants discussed the need to repurchase drugs at inflated prices due to the discovery of their parallel trading activities [5][9] - The market price for the product in question, the Shenqi Jiangtang capsule, is reported to be between 55-58 yuan, while the defendants were selling it at a significantly lower price, impacting normal sales operations [2][9] Group 2: Financial Implications - The prosecution claims that the defendants forced companies to repurchase drugs at inflated prices, with total extortion amounts reaching over 20.85 million yuan [10][11] - Specific examples of inflated repurchase demands include a request to repurchase drugs for 2.17 million yuan that were originally purchased for 970,000 yuan [11] - The case raises questions about the legality of pricing strategies in the pharmaceutical industry, particularly regarding low-price online sales and their impact on market stability [10][11]